Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Februar 2026 09:00 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™...
17. Februar 2026 08:05 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request...
11. Februar 2026 08:45 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
06. Januar 2026 08:35 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
31. Dezember 2025 16:15 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
26. Dezember 2025 17:00 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
19. Dezember 2025 08:05 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
24. November 2025 09:05 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
13. November 2025 08:30 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...
03. November 2025 08:35 ET | Quelle: Outlook Therapeutics, Inc.

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

Nächste Seite